SCHEMBL5881277

SCHEMBL5881277

O=[C]C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6131429 1.00 MEN1 (0.33) MEN1KMT2ATDP1
SCHEMBL16295072 0.65 MEN1 (0.62) MEN1KMT2ATDP1
SCHEMBL61759 0.65 MEN1 (0.62) MEN1KMT2ATDP1
SCHEMBL812362 0.65 MEN1 (0.62) MEN1KMT2ATDP1
SCHEMBL693244 0.65
SCHEMBL554655 0.65 MEN1 (0.62) MEN1KMT2ATDP1
Perfluorocyclobutane SCHEMBL24521 0.65 MEN1 (0.62) MEN1KMT2ATDP1
SCHEMBL396358 0.65 MEN1 (0.62) MEN1KMT2ATDP1
SCHEMBL7260823 0.65 MEN1 (0.62) MEN1KMT2ATDP1
Perfluorocyclobutane SCHEMBL4916072 0.59 MEN1 (0.56) MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9403863-B2 Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections IDENIX PHARMACEUTICALS LLC (US) 2016-08-02 US claimed
EP-2755983-B1 SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS IDENIX PHARMACEUTICALS LLC (US) 2017-03-15 EP disclosed
US-7105618-B2 Fluorine-containing polymerizable monomers and polymers, anti-reflection film materials and resist compositions using same CENTRAL GLASS COMPANY, LIMITED (JP) 2006-09-12 US disclosed
EP-1538168-A1 METHOD OF OBTAINING PERFLUOROSULPHONATE POLYMERS CONTAINING SULPHONYL FUNCTIONAL GROUPS DAVID FUEL CELL COMPONENTS, S.L. (ES) 2005-06-08 EP disclosed
US-20030232940-A1 Fluorine-containing polymerizable monomers and polymers, anti-reflection film materials and resist compositions using same CENTRAL GLASS COMPANY, LIMITED (JP) 2003-12-18 US disclosed
US-6511787-B2 Acrylic resin containing hexafluoroisopropanol units having high transmittance to ultraviolet radiation having high transparency, substrate adhesion, alkali development, and acid-elimination capability for lithographic microprocessing SHIN-ETSU CHEMICAL CO., LTD. (JP) 2003-01-28 US disclosed
US-20020048724-A1 Polymers, resist compositions and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2002-04-25 US disclosed
US-4400532-A PRODUCTION OF TRIFLUOROACETIC ACID FROM ETHYL ACETATE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1983-08-23 US disclosed
US-4281119-A Cryogenically controlled direct fluorination process, apparatus and products resulting therefrom MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1981-07-28 US disclosed
US-4113435-A CRYOGENICALLY CONTROLLED DIRECT FLUORINATION APPARATUS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1978-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232940-A1 Fluorine-containing polymerizable monomers and polymers, anti-reflection film materials and resist compositions using same AFF1, AFF4, AFF2 MEN1 731/4885KMT2A 513/4885TDP1 1160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.